Dr. Ramzi Khamis is a Clinical Senior Lecturer in Cardiology and a consultant cardiologist, with a subspecialty in interventional cardiology. Ramzi is the Clinical Director for Cardiology and Cardiac Surgery at Imperial College Healthcare NHS Trust. He also leads the high risk atherosclerosis clinic at Imperial college Healthcare NHS Trust.
Ramzi holds a Fellowship from the British Heart Foundation as a clinician scientist in Cardiovascular Medicine. He undertakes both his clinical and research work at the Hammersmith Hospital Campus.
Dr. Khamis was trained in general cardiology, interventional cardiology and translational cardiovascular medicine at Imperial College and its affiliated hospitals. Dr. Khamis completed his interventional cardiology fellowships at the Hammersmith Hospital. He was awarded his consultant level accreditation (CCT) in both G(I)M and cardiology from the Royal College Of Physicians, and PhD from Imperial college London in 2014. Dr. Khamis is also a fellow of the European Society of Cardiology (FESC). Dr. Khamis first graduated from Bristol in 2000, and undertook his House Officer training at Bristol and Bath followed by Emergency Medicine training in Leeds, and then by General Internal Medicine training as part of the Barts and the London Medical SHO training scheme in London. Dr. Khamis also taught physiology at Bristol University as a tutor in 2002.
He was awarded and completed a highly competitive Academic Clinical Fellowship in Cardiology, encompassing both clinical and academic training, funded by the National Institute for Health Research (NIHR) at the National Heart and Lung Institute, as well as competitive Fellowships in Interventional Cardiology at the Hammersmith Hospital London in 2009-10 and 2013-14. He was also awarded a Wellcome Trust/ GSK Clinical Research Fellowship in Translational Medicine, undertaking his PhD under the Supervision of Profs Haskard and Matthews.
His research interests include the development of a multimodality imaging strategy for the detection of vulnerable plaque in atherosclerosis, developing novel biomarkers in cardiovascular risk assessment and the understanding the role of antibodies in atherosclerosis.
In 2014, Dr Khamis was the winner of the British Cardiovascular Society Young Research Worker of the Year Award and a finalist at the American College of Cardiology Young Investigator of the Year Award. He was also British Atherosclerosis Society Young Investigator of the Year finalist 2013 and the winner of the British Atherosclerosis Binks travel award (Harvard Medical School) 2013.
Dr. Khamis group encompasses both clinicians and scientists focusing on the targeting of oxidised LDL in atherosclerosis using interventional and non interventional modalities such as near infra-red fluorescence (NIRF) imaging and positron emission tomography (PET). He also undertakes research to explore the mechanistic link between the humeral immune system and atherosclerosis. Dr. Khamis' group are developing various serological tests to better risk stratify cardiac risk in patients and populations.
During COVID-19 pandemic, Ramzi's efforts were on the COVID reposes and was the co-head of cardiology at Imperial College HNT.
Dr. Khamis co-organised the Imperial College COVID-19 Cardiovascular Conference which highlights the current knowledge and cumulative experience to date , on 2 April 2020. Click here to watch the recording
et al., 2021, Near-Infrared Autofluorescence in Atherosclerosis Associates With Ceroid and Is Generated by Oxidized Lipid-Induced Oxidative Stress, Arteriosclerosis Thrombosis and Vascular Biology, Vol:41, ISSN:1079-5642, Pages:E385-E398
et al., 2021, Placebo-controlled efficacy of percutaneous coronary intervention for focal and diffuse patterns of stable coronary artery disease, Circulation: Cardiovascular Interventions, ISSN:1941-7640
et al., 2021, COVID-19 and its impact on the cardiovascular system, Open Heart, Vol:8, ISSN:2053-3624, Pages:1-9
et al., 2021, Achieving optimal adherence to medical therapy by telehealth: Findings from the ORBITA medication adherence sub-study, Pharmacology Research and Perspectives, Vol:9, ISSN:2052-1707, Pages:e00710-e00710
et al., 2021, Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a), Antioxidants, Vol:10, ISSN:2076-3921